Business
Janux Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights
-IND application recently submitted for PSMA-TRACTr (JANX007)- -Company remains on-track to submit IND application for EGFR-TRACTr (JANX008) in 2H 2022-
About this update from Janux Therapeutics, Inc.
[{"type":"text","content":"\n-IND application recently submitted for PSMA-TRACTr (JANX007)-\n\n-Company remains on-track to submit IND application for EGFR-TRACTr (JANX008) in 2H 2022-\n\n-Merck nominates second target as part of strategic collaboration and license agreement-\n\n-Presented preclinical data for JANX007 and JANX008 at the 18th Annual Protein & Antibody Engineering Summit (PEGS) Boston Conference & Expo-\n\n-$361.2 million in cash and cash equivalents and short-term investments at end of first quarter 2022-\n\n SAN DIEGO--(BUSINESS WIRE)--\nJanux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today reported financial results for the first quarter ended March 31, 2022 and provided a business update.\n\n“Janux continues to make meaningful progress towards our goal of developing next-generation immunotherapies that are uniquely designed to overcome the clinical limitations of existing TCE approaches,” said David Campbell, Ph.D., President and CEO of Janux. “Recently, we were pleased to have presented compelling preclinical data supporting the planned clinical development of both our lead TRACTr programs at PEGS Boston, and we are excited about our progress in advancing IND application submissions for JANX007 and JANX008 in 2022. In tandem, we continue to advance our TROP2-TRACTr and our PD-L1xCD28 costimulatory TRACIr programs, with the goal of submitting an IND for both in 2023. We look forward to driving our pipeline of next-generation immunotherapies into the clinic and executing on our near-term milestones.”\n\nRECENT BUSINESS HIGHLIGHTS AND FUTURE MILESTONES:\n\n\nTRACTr candidates advancing as planned.\n\n\nJanux recently submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) for its PSMA-TRACTr (JANX007). cGMP manufacturing of drug substance and drug product has been completed to support the IND and supply first-in-human (FIH) clinical studies.\n\n\nJanux expects to submit an IND application to the FDA for its EGFR-TRACTr (JANX008) in the second half of 2022. cGMP manufacturing of drug substance has been completed to support the IND and supply FIH clinical studies.\n\n\nJanux...